Top insider buys and sells disclosed on Friday
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Krystal Biotech Inc (KRYS)
The Krystal Biotech share price today is 343.34, view NASDAQ KRYS stock exchange data. Track the latest Krystal Biotech share price with real-time updates on KRYS stock performance including market cap, day range, 52-week range and dividend yield. Access KRYS charts, earnings dates and analyst estimates to support your investment decisions.
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
335.44
345.56
52 wk Range
136.73
382.54
KRYS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
335.44345.56
52 wk Range
136.73382.54
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
KRYS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
385.00
Upside
+12.13%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
Krystal Biotech receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Top insider buys and sells disclosed on Friday
- Investing.com
- Krystal Biotech receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Krystal Biotech receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
10 Buy
1 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 385.00
(+12.13% Upside)
Krystal Biotech Inc Earnings Call Summary for Q2/2026
- Krystal Biotech Q2 EPS of $1.79 beat estimates by $0.09, but revenue of $119.2M missed forecasts by 2.5%; shares fell 6.95% to $317.40.
- VYJUVEK global revenue rose 24% YoY; gross margin improved to 95% from 93%; company secured 730+ U.S. reimbursement approvals, exceeding targets.
- Net income jumped 43% to $54.8M; cash and investments exceeded $1.1B; full-year operating expense guidance held at $175M-$195M unchanged.
- European pricing negotiations in Germany, Italy, Spain expected to conclude by end-2026; France discussions likely extending into 2027.
- Pipeline readouts expected for KB803, KB407, KB111 by year-end 2026; KB801 enrollment to finish end-2026 with data in early 2027.
Last Updated: 03-08-2026, 07:14 pm
Read Full TranscriptEarnings
Latest Release
03-08-2026
EPS / Forecast
1.79 / 1.70
Revenue / Forecast
119.2M / 122.3M
Compare KRYS to Peers and Sector
Metrics to compare | KRYS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKRYSPeersSector | |
|---|---|---|---|---|
P/E Ratio | 42.1x | −2.2x | −0.3x | |
PEG Ratio | 0.67 | −0.23 | 0.00 | |
Price/Book | 7.5x | 5.5x | 2.6x | |
Price / LTM Sales | 23.1x | 39.3x | 3.1x | |
Upside (Analyst Target) | 14.6% | 194.7% | 48.5% | |
Fair Value Upside | Unlock | 10.8% | 6.3% | Unlock |
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Krystal Biotech (KRYS) Share Price Today?
The Krystal Biotech share price today is 343.34.
What is the current Krystal Biotech (KRYS) share price and day range?
As of 20-08-2026, the Krystal Biotech share price is 343.34, with a previous close of 332.82. The share price has ranged from 335.44 to 345.56 today, while the 52-week range spans from 136.73 to 382.54.
What Is the Krystal Biotech Market Cap?
As of today, Krystal Biotech market cap is 10.16B.
What Is the Krystal Biotech (KRYS) Share Price Target?
The average 12-month share price target for Krystal Biotech is 385.00, with a high estimate of 474 and a low estimate of 284. 10 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +12.13% Upside potential.
What Is Krystal Biotech's Earnings Per Share (TTM)?
The Krystal Biotech EPS (TTM) is 7.97.
When Is the Next Krystal Biotech Earnings Date?
Krystal Biotech will release its next earnings report on 09-11-2026.
From a Technical Analysis Perspective, Is KRYS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Krystal Biotech Trade On?
Krystal Biotech is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Krystal Biotech?
The stock symbol for Krystal Biotech is "KRYS."
How Many Times Has Krystal Biotech Stock Split?
Krystal Biotech has split 0 times.
How Many Employees Does Krystal Biotech Have?
Krystal Biotech has 295 employees.
What Is the KRYS Premarket Price?
KRYS's last pre-market stock price is 339.07. The pre-market share volume is 585.00, and the stock has changed by 6.25, or 1.88%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.